RxDoctor Payments Data

Nathan Cleaver, DO

Dermatology · Cumming, GANPI 1871882225

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $25,546 of the $38,362 with a category attached, or 66.6%. 40 manufacturers reported payments, led by Sun Pharmaceutical Industries Inc. at 30.6% of the total. 2025 is the largest year on record at $23,530, more than ten times the $1,167 reported in 2019. Among dermatology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$38,362in general payments, 2019–2025

Across 423 payments — averaging $90.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$12K
  • Sanofi US Services Inc.$10K
  • UCB, Inc.$6K
  • AbbVie$3K
  • Johnson & Johnson$2K
  • Sanofi$967
  • plus $5K from 34 others
$597,644in research payments, 2019–2025

Across 78 payments — averaging $7662.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$376K
  • Sanofi US Services Inc.$172K
  • Incyte Corporation$50K

What the payments were for

  • Consulting fees$25,54667%
  • Travel & lodging$1,0893%
  • Food & beverage$11,44130%
  • Education$2851%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,362 in reported general payments places this provider in the 90th percentile of 345 dermatology providers in Georgia.

See all dermatology providers in Georgia

Medicare billing

Part B allowed, 2024
$986,626
Medicare patients
1,825
Services billed
11,637

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast12$59,616
Dupixent PenDupilumab16$59,593
Fluorouracil46$3,490
Ketoconazole156$2,305
Clobetasol Propionate34$1,392
Cephalexin97$1,227
Mupirocin185$1,107
Fluocinonide33$1,081
Betamethasone Dipropionate17$800
Triamcinolone Acetonide61$787
Metronidazole12$519
Ciclopirox14$507
Imiquimod15$471
Ammonium Lactate28$467
Hydrocortisone35$416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$50$59,61612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 345 dermatology providers in Georgia.

Other dermatology in Cumming

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →